Bank Julius Baer & Co. Ltd Zurich Reduces Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Bank Julius Baer & Co. Ltd Zurich trimmed its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 8.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 84,313 shares of the medical device company's stock after selling 8,158 shares during the period. Bank Julius Baer & Co. Ltd Zurich's holdings in DexCom were worth $6,049,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd boosted its stake in shares of DexCom by 82.6% during the first quarter. Y Intercept Hong Kong Ltd now owns 30,282 shares of the medical device company's stock valued at $2,068,000 after purchasing an additional 13,698 shares in the last quarter. Peterson Wealth Services boosted its position in DexCom by 16.3% during the 1st quarter. Peterson Wealth Services now owns 3,524 shares of the medical device company's stock valued at $241,000 after acquiring an additional 494 shares in the last quarter. Los Angeles Capital Management LLC boosted its position in DexCom by 287.0% during the 1st quarter. Los Angeles Capital Management LLC now owns 313,796 shares of the medical device company's stock valued at $21,429,000 after acquiring an additional 232,705 shares in the last quarter. Sargent Investment Group LLC bought a new stake in DexCom during the 1st quarter valued at $906,000. Finally, Teachers Retirement System of The State of Kentucky boosted its position in DexCom by 16.7% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 136,968 shares of the medical device company's stock valued at $9,353,000 after purchasing an additional 19,607 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

DexCom Stock Performance

NASDAQ DXCM traded up $2.25 during trading hours on Friday, hitting $88.99. 3,072,147 shares of the stock were exchanged, compared to its average volume of 2,733,721. The company has a market cap of $34.89 billion, a price-to-earnings ratio of 66.41, a price-to-earnings-growth ratio of 1.85 and a beta of 1.44. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $93.25. The stock has a 50-day moving average of $84.58 and a 200 day moving average of $80.41. The company has a quick ratio of 1.32, a current ratio of 1.50 and a debt-to-equity ratio of 0.55.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). The business had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a return on equity of 30.05% and a net margin of 12.90%. The company's revenue was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.32 EPS. As a group, equities research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Activity at DexCom

In other DexCom news, Director Nicholas Augustinos sold 3,672 shares of the stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $82.80, for a total value of $304,041.60. Following the completion of the transaction, the director directly owned 33,411 shares of the company's stock, valued at approximately $2,766,430.80. This trade represents a 9.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Sadie Stern sold 6,184 shares of DexCom stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total value of $526,320.24. Following the transaction, the executive vice president directly owned 109,621 shares of the company's stock, valued at approximately $9,329,843.31. This represents a 5.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 27,190 shares of company stock worth $2,281,732. 0.32% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

DXCM has been the subject of a number of recent analyst reports. Barclays raised their price objective on DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research report on Monday, May 5th. Mizuho lifted their target price on shares of DexCom from $95.00 to $100.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 16th. Citigroup restated a "buy" rating and issued a $102.00 price target (up from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Truist Financial started coverage on DexCom in a research report on Monday, June 16th. They issued a "buy" rating and a $102.00 price objective for the company. Finally, Wall Street Zen upgraded DexCom from a "hold" rating to a "buy" rating in a research report on Friday, July 18th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $99.60.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.